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Pan-drug resistant Gram-negative bacteria, being resistant to most available antibiotics,
represent a huge threat to the medical community. Colistin is considered the last thera-
peutic option for patients in hospital settings. Thus, we were concerned in this study to
demonstrate the membrane permeabilizing activity of colistin focusing on investigating its
efﬁciency toward those pan-drug resistant isolates which represent a critical situation. We
determined the killing dynamics of colistin against pan-drug resistant isolates. The perme-
ability alteration was conﬁrmed by different techniques as: leakage, electron microscopy
and  construction of an artiﬁcial membrane model; liposomes. Moreover, selectivity of col-
istin  against microbial cells was also elucidated. Colistin was proved to be rapid bactericidal
against pan-drug resistant isolates. It interacts with the outer bacterial membrane leading
to  deformation of its outline, pore formation, leakage of internal contents, cell lysis and
ﬁnally death. Furthermore, variations in membrane composition of eukaryotic and micro-
bial cells provide a key for colistin selectivity toward bacterial cells. Colistin selectively alters
membrane permeability of pan-drug resistant isolates which leads to cell lysis. Colistin was
proved to be an efﬁcient last line treatment for pan-drug resistant infections which are hard
to  treat.
© 2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ntroduction
ecently, it has been witnessed worldwide that Gram-negative
acteria resistant to many  classes of antibiotics represents
 fearful situation toward the emergence of a future medi-
al disaster.1 There are 2 terms commonly describing those
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drug resistant (PDR). An isolate is considered MDR  if it exhib-
ited resistance toward 5 out of the 7 anti-pseudomonal classes
of antimicrobial agents, i.e. anti-pseudomonal penicillins,nt, Faculty of Pharmacy, Alexandria University, Egypt.
cephalosporins, carbapenems, monobactams, quinolones,
aminoglycosides, and colistin, while it is a PDR  if it showed
resistance toward all 7 anti-pseudomonal antimicrobial
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agents, including colistin.2 There was another view consid-
ering that PDR isolates were those resistant to all antibiotics
but only susceptible to polymyxins.3,4 Although there is no
apparent deﬁnition for the term PDR throughout literature, it
generally denotes resistance against a variety of antibiotics
excluding polymyxins.5 Such view is adopted in the present
work. In the past few decades there have been a tremendous
increase in resistance to currently available antibiotics and a
signiﬁcant decline in development of new ones.6 This leads to
the revival of older agents as polymyxins, for the treatment of
such PDR infections.2
Polymyxins are a group of polypeptide cationic antibiotics
that were isolated from Bacillus polymyxa in the 1940s.7 Since
then, polymyxin E (colistin) and polymyxin B were extensively
used in clinical practice for Gram-negative organisms.8,9 How-
ever, they were gradually withdrawn from the market and
abandoned during the last two decades due to claimed reports
of toxicity. Therefore, during that time, there have been limited
studies on the clinical use, pharmacokinetics and pharma-
codynamics of colistin.10 Emergence of the PDR pathogens,
necessitated the re-evaluation of polymyxin therapies.11
Colistin has been recently considered as last option treat-
ment for patients with nosocomial PDR infections, which have
become an important public health issue, owing to its favor-
able properties of rapid bacterial killing, a narrow spectrum
of activity, and slow development of resistance.12,13 Colistin
interacts electrostatically with the outer membrane of Gram-
negative bacteria and competitively displaces divalent cations
which stabilize the lipopolysaccharide layer thus disrupting
the membrane integrity. It is then subsequently taken up via
the self-promoted uptake pathway.13 It is believed that col-
istin forms cracks in the outer membrane which promotes its
uptake inside the cell and permits the passage of different
molecules.14 Thus, polymyxins produce a disruptive detergent
effect, leading to increased permeability in the outer mem-
brane, leakage of the absorbing cytoplasmic contents, cell
lysis and ﬁnally death.15 The chemical composition of bacte-
rial membranes being rich in phosphatidylethanolamine and
negatively charged lipids allows such electrostatic attraction
with cationic peptides in contrast to eukaryotic cells in which
cholesterol is the predominant component providing a clue for
the selectivity of action toward microbial versus host cells.16
Such a situation prompted the present microbiological study
to investigate the membrane permeability alteration of col-
istin and it bactericidal effect on PDR Gram-negative clinical
isolates including Acinetobacter baumannii,  Pseudomonas aeru-
ginosa,  Klebsiella pneumoniae and Escherichia coli.
Materials  and  methods
Microorganisms  and  antibiotics
Four clinical bacterial isolates, identiﬁed by classical micro-
scopic and biochemical procedures,17,18 were used in this
study. These are: A. baumannii (A182), P. aeruginosa (P103),
E. coli (E9) and K. pneumoniae (K103). The identiﬁed iso-
lates were maintained by freezing in 15% glycerol broth 19
(Oxoid Ltd.; Basingostok; Hampshire, England). Colistin sul-
phate was obtained as powder from Pharco pharmaceutical b i o l o g y 4 7 (2 0 1 6) 381–388
Co., Egypt. It was dissolved in water to prepare stock solu-
tions. The susceptibility of the tested isolates, to the different
classes of antibiotics was determined by the standard disc
agar diffusion technique according to Bauer et al.20 with
some modiﬁcations.21 MIC  of colistin was determined by the
standard broth dilution technique.22
Bactericidal  activity  of  colistin  using  the  viable  count
technique
For each tested isolate, two concentrations of colistin (1/2MIC
and MIC) were prepared in sterile nutrient broth. Each concen-
tration was inoculated with overnight culture to give a ﬁnal
inoculum of 106 cfu/mL. A control without antibiotic was pre-
pared for each of the tested isolates. The systems were mixed
well and incubated at 37 ◦C with shaking. Samples were asep-
tically withdrawn from each test tube at 0, 1, 3, 6 and 24 h and
serially diluted with sterile saline. Then, 10 L portions were
dropped onto the surface of overdried nutrient agar plates. The
plates were left to dry and incubated inverted at 37 ◦C for 24 h,
the resulting colonies were counted and the original viable
count was determined.23
Effect  of  colistin  on  the  cytoplasmic  membrane  by  leakage
technique
Bacterial suspensions of the selected isolates were prepared by
streaking an overnight broth culture onto nutrient agar slants
(Oxoid Ltd.; Basingostok; Hampshire, England). The slants
were incubated at 37 ◦C for 16–18 h. The resulting growth of 3
slants was resuspended in 5 mL  sterile 0.9% saline to produce
heavy inoculum (O.D600 adjusted to 2) and transferred into
sterile test tubes. The obtained bacterial suspensions were
centrifuged at 12,000 × g for 5 min. The formed pellets were
washed twice with sterile saline and then were resuspended
in 5 mL sterile saline. Aliquots of the prepared bacterial sus-
pension of each isolate were treated with 50 mg/L of colistin.
A control was included in each test containing untreated bac-
terial suspension. Both the treated and untreated bacterial
suspensions were incubated at 37 ◦C for 24 h. After incubation,
the bacterial suspensions were centrifuged at 12,000 × g for
5 min. The absorbance of the clear supernatant was estimated
at 260 and 280 nm against saline solution using the spec-
trophotometer (Thermospectronic, Helios alpha, NC 9423UV
A 1002E, England).24
Effect  of  colistin  on  the  leakage  of  red  blood  cells
One milliliter of fresh human blood was centrifuged at 2000 × g
for 5 min  and the cells were washed 4× with sterile 0.9% saline
discarding the supernatant every time. The sedimented red
blood cells (RBCs) were resuspended in 1 mL  buffer (5 mM
sodium phosphate and 150 mM sodium chloride [pH 7.4]). The
RBCs suspension in buffer was distributed in sterile eppen-
dorf tubes in 25 L aliquots and 1 mL  of colistin solution
dissolved in the same buffer was added to each eppendorf
in concentrations ranging from 0.78 mg/L to 100 mg/L. The
resulting suspensions were incubated at room temperature for
2 h. The systems were then centrifuged at 2000 × g for 10 min.
The release of hemoglobin was monitored by measuring the
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Table 1 – MIC  of colistin against PDR clinical isolates.
Isolate code MIC (mg/L)
A182 1.25
P103 0.625b r a z i l i a n j o u r n a l o f m i c 
bsorbance of the supernatant at 540 nm by spekol (Carl Zeiss,
ena, Germany). Absorbance of control untreated cells in saline
as measured and used as a blank. Total haemolysis was
lso measured by lysing colistin-untreated RBCs with distilled
ater.25
ffect  of  colistin  on  the  ultrastructure  of  bacterial  cells
sing the  transmission  electron  microscope
wo clinical isolates were used in this study; a sensitive and
n induced resistant population for each isolate. The resis-
ance was induced by serial passaging in increasing colistin
oncentrations. 0.5 mL  of overnight broth culture was inocu-
ated in ﬂasks containing 50 mL sterile nutrient broth. Flasks
ere incubated in the orbital shaking incubator (100 rpm) at
7 ◦C till reaching acceptable turbidity for about 4–5 h. The
elected clinical isolates were treated with 100 mg/L of col-
stin for 1 h. Proper controls lacking colistin were included for
ach isolate population. The obtained bacterial suspensions
ere centrifuged at 6000 × g for 5 min. The supernatants were
iscarded. The obtained colistin-treated and control bacterial
ellets were then resuspended in 3 mL  Trump’s ﬁxative solu-
ion and further processed as previously described.26,27 The
amples were examined and photographed at an accelerat-
ng voltage of 80 kV using Joel CX 100 transmission electron
icroscope at the Electron Microscope Unit, Faculty of Sci-
nce, Alexandria University.
ffect  of  colistin  on  the  cytoplasmic  membrane  using
rtiﬁcial  cytoplasmic  membrane  model
egatively-charged unilamellar cholesterol free liposomes
ere prepared by reverse-phase evaporation method.28 The
iposomes were then treated by colistin (100 mg/L) for 24 h and
ere morphologically examined by the phase contrast micro-
cope (Olympus, CX 41 RF) using oil-immersion objective lens
100×) for any damage in their shape following colistin treat-
ent.
ffect  of  colistin  on  the  formation  of  spheroplasts
ne hundred L of exponential cell culture, adjusted to have
.D600 of 0.05 were inoculated into 3 mL  Müller-Hinton broth
ontaining 0.3 M of sucrose and were mixed well. Then,
liquots of 100 L were distributed in sterile eppendorf tubes.
en L of colistin were added to 3 eppendorfs in concentration
f 1/2 MIC. Ten L of ceftazidime were added to 3 other eppen-
orfs in concentration of 1/2 MIC. A control eppendorf was
ncluded containing 0.9% saline instead of antibiotic solution.
he eppendorfs were incubated in the orbital shaking incu-
ator at 37 ◦C, 100 × g for 90 min. Samples were then taken
nd examined by the phase contrast microscope using oil-
mmersion objective lens (100×).
esults  and  discussionlobally, there is a growing threat from the emergence of MDR
nd PDR organisms especially Gram-negative bacteria, such as
. aeruginosa,  A. baumannii,  Klebsiella and Enterobacter species inE9 0.625
K103 1.25
hospital settings.29 PDR pathogens represent a fearful clinical
situation with tremendous implications. So, this study aimed
at investigating the deleterious effects of colistin on those PDR
pathogens. The four bacterial isolates used in this study were
conﬁrmed to be pan-drug resistant by the antibiotic suscep-
tibility testing being resistant to all antibiotic classes except
colistin (data not shown). The MIC of colistin against the tested
isolates ranged from 0.625 to 1.25 mg/L as determined by broth
dilution method (Table 1). All the tested isolates were sensitive
to colistin according to the CLSI resistance breakpoint which
is 4 mg/L (Table 1).
The dynamics of killing of colistin was determined by the
viable count technique against the tested isolates using ½
MIC  and MIC of colistin. Colistin was shown to be a rapid
bactericidal agent in a concentration dependent manner in
all the tested PDR isolates. Rapid and signiﬁcant declines
(>2 log) in bacterial survival were observed after 3 h in all the
tested isolates at 1/2 MIC level reaching almost 6 logs at the
MIC  level. The rapid bactericidal activity of colistin is related
to its permeabilizing action on the cell membrane following
self-promoted uptake.30 However, re-growth was observed as
early as 6 h and substantial re-growth occurred at 24 h in all
the tested PDR clinical isolates at 1/2MIC while only 2 iso-
lates showed re-growth at the MIC  level (Fig. 1). This might
be caused by the heteroresistant subpopulations which grow
probably at a slower rate than the sensitive subpopulation
and hence, temporary inhibition could be mistaken. This phe-
nomenon is of potential risk as it can lead to therapy failure if
colistin monotherapy is used.31
A leakage study was conducted to conﬁrm the mem-
brane permeability alteration effect of colistin. The effect
of 50 mg/L of colistin on the cytoplasmic membrane against
4 representative PDR clinical isolates was determined spec-
trophotometrically. The difference between the values of
absorbance at 260 and 280 nm of the supernatant of both the
treated cells and the untreated cells corresponding to the net
leakage due to treatment is illustrated in Fig. 2.
Colistin resulted in a net loss of 260 and 280 nm-absorbing
materials. The extent of leakage differed from one organism
to another. The maximum leakage was observed for the P103
isolate.
This leakage effect is due to the destabilization of mem-
brane integrity arising after the electrostatic interaction of
colistin with the outer membrane displacing the divalent
cations from the LPS layer.32 This results in an increase in the
permeability of cell membrane, leakage of cell contents and
ﬁnally cell death.
Furthermore, to demonstrate the selectivity of colistin
toward microbial membranes, the effect of colistin on the
haemolysis of human RBCs was studied. The release of
hemoglobin was monitored by measuring the absorbance
of the supernatants of the different reaction mixtures at
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Fig. 1 – Bactericidal activity of colistin against PDR isolates. (A) A. baumannii (A182), (B) P. aeruginosa (P103), (C) K. pneumonie
(K103) and (D) E. coli (E9). Filled circles represent the control untreated cells, ﬁlled squares represent 1/2 MIC  of colistin, ﬁlled
triangles represent MIC  of colistin.
540 nm by the spekol. Then, the per cent of haemolysis
of RBCs was calculated. It is shown in Fig. 3 that the per
cent of RBCs haemolysis increased by increasing colistin
concentration. It produced about 1.3% haemolysis at a con-
centration of 12.5 mg/L which is nearly more  than ten times
the average MIC  of the tested PDR clinical isolates. At low
concentrations, it produced insigniﬁcant haemolysis less than
1%. However, there was a sharp increase in the per cent
of haemolysis at concentrations above 50 mg/L which are
unachievable in vivo. This conﬁrms the selectivity of col-
istin toward the cytoplasmic membrane of the bacterial cells
and denotes its in vivo safety at the normal administered
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Fig. 2 – Leakage of absorbing materials from PDR clinical
isolates in the presence of colistin. White bars represent
260 nm absorbing materials and black bars represent
280 nm absorbing materials.doses. The composition of bacterial cells being rich in anionic
phosphatidylglycerol and cardiolipin likely provides an impor-
tant determinant for antimicrobial cationic peptides to target
microbial membranes.33
Another evidence for the damaging effect of colistin on the
cell envelope is obtained by electron microscope examination.
The effect of colistin on the ultrastructure of 2 representative
isolates (A182 and P103) was studied. The cells (sensitive
and induced resistant) were treated by 100 mg/L of colistin
for 30 min, centrifuged, ﬁxed and prepared by encapsulating
and cutting ultra thin sections from treated and untreated
bacterial cell sediments followed by examination of the pre-
pared section under the transmission electron microscope.
A smooth continuous cell wall and cytoplasmic membrane
structures were observed in the untreated sensitive bacterial
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Fig. 3 – Effect of different concentrations of colistin on
haemolysis of RBCs.
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Fig. 4 – Ultrastructure of colistin treated A. baumannii cells. (A1,2,3): Sensitive A. baumannii A182 cells, (B1,2,3): Resistant
(induced) A. baumannii A182 cells, A1 and B1 represent the control untreated cells for each category. Magniﬁcation: 40,000×:
A
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m
w
c
m
p2, A3, B3 and 50,000×:  A1, B1, B2.
trains. However, a slightly wavy cytoplasmic outline was
bserved for the induced resistant one (Fig. 4). Colistin-
reated cells showed numerous projections and pores on the
ell wall which was almost dissolved whereas the cytoplas-
ic  membrane was partially damaged. The contents of some
reated cells appeared depleted as part of the cytoplasmic
aterial was released through cracks. Such phenomenon
as more  apparent with the sensitive isolates than with the
orresponding isolates with induced colistin resistance (Fig. 5).
Moreover, the effect of colistin on an artiﬁcial cytoplasmic
embrane model was determined by examination under the
hase contrast microscope. The effect of colistin (100 mg/L)on the negatively-charged unilamellar cholesterol free lipo-
somes compared to the control untreated ones is illustrated in
Fig. 6. Colistin resulted in an overall deformation in the struc-
ture of the artiﬁcial cytoplasmic membrane model. Various
effects were observed on the phospholipid membrane ranging
from roughness and distortion of the outline, pore formation
and complete rupture of the membrane and liberation of the
internal contents.It was a thought of interest whether colistin affects only the
outer membrane or it also affects the cell wall. So, the effect of
colistin on the cell wall was compared to that of ceftazidime
which is a -lactam antibiotic known to act on the cell wall
386  b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 7 (2 0 1 6) 381–388
Fig. 5 – Ultrastructure of colistin treated P. aeruginosa cells. (A1,2,3): Sensitive P. aeruginosa P103 cells, (B1,2,3): Resistant
(induced) P. aeruginosa P103 cells, A1 and B1 represent the control untreated cells for each category. Magniﬁcation: 30,000×:
A3, B1, B2, 40,000×:  A1, B3 and 50,000×: A2.by using the isolate P103. Ceftazidime causes spheroplast
formation prior to cell lysis in Gram-negative bacteria due
to inhibition of transpeptidases (Penicillin-Binding Proteins)
which catalyze the cross linking of peptidoglycan chains.
Thus, it disrupts the synthesis of peptidoglycan resulting in
the release of autolysins which enzymatically degrade the
cell walls forming spheroplast, which is osmotically-sensitive
34cell lacking rigidity of the cell wall. Sucrose 0.3 M acts
as a stabilizer for the formed spheroplasts. By using sub-
inhibitory concentrations of ceftazidime in the present study,
spheroplasts were formed and viewed by the phase contrastmicroscope (Fig. 7). When comparing that to colistin, similar
structures were obtained at 1/2 MIC level. Formation of such
osmotically unstable structures indicates that colistin not only
acts on the cytoplasmic membrane but also on the cell wall.
Therefore, it could be assumed that treatment of sensitive
Gram-negative cells with colistin in the presence of hyper-
tonic solution might have resulted in the release of autolysins
which degraded most of the cell wall leaving spheroplasts sup-
ported by the surrounding high osmotic pressure.35 Hence,
it can be elucidated that colistin acts on multiple layers
of Gram-negative cells, initially on the outer membrane as
b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 7 (2 0 1 6) 381–388 387
Fig. 6 – Morphology of liposomes examined under oil-immersion objective lens (total magniﬁcation 1000×). (A) Untreated
control, (B) Colistin-treated [additional optical zoom: A1 and B1 (2×),  A2 and B2 (3×)].
Fig. 7 – Spheroplasts of P103 isolate formed at ½ MIC  of ceftazidime (B) and colistin (C) in hypertonic solution compared to
shape of control cells (A).
 i c r o
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demonstrated by the electron microscopy study and then on
the inner membrane as shown by the spheroplasts data.
In conclusion, it can be demonstrated that colistin is still
a promising drug for the treatment of infections due to PDR
clinical isolates. It induces alterations in the permeability of
the bacterial cytoplasmic membrane, leakage of the intra-
cellular contents and ultimately cell death. However, colistin
should not be misused to avoid the global problem of devel-
opment of resistance. Further in vivo investigations are still
required concerning the pharmacokinetics, pharmacodynam-
ics and toxicodynamics of colistin.
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